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Acute Glomerular Diseases in Children
Kanwal K. Kher*
Division of Nephrology, Children's National Medical Center, The George Washington University School of Medicine
and Healthy Sciences, Washington, DC, USA
Abstract: Glomerulonephritis [GN] is one of the common acquired pediatric renal disorders encountered in clinical
practice. The clinical manifestations include gross or microscopic hematuria, proteinuria, and nephrotic syndrome. Renal
dysfunction and hypertension may also be present in many patients. Etiopathogenesis of GN can be idiopathic in a large
majority, while some may result from infections or known immune disorders. Several of these disorders are now believed
to arise from dysfunctions of podocytes and are grouped under the heading of “podocytopathies”. This review focuses on
the clinical manifestations and management of the common forms of acute GN encountered in children.

Keywords: Acute post-streptococcal glomerulonephritis, Glomerulonephritis, Henoch-Schönlein purpura, IgA nephropathy,
lupus nephritis.
INTRODUCTION
In the pre-renal biopsy era, most forms of nephritis and
nephrotic syndrome were consdered as “Bright’s disease”
[1]. With a better understanding of the pathology and
pathogenesis of renal diseases, the term glomerulonephritis
[GN] is used in the contemporary scientific literature to
define non-infectious inflammatory lesion affecting the
glomeruli. The clinical manifestations of GN encompass a
spectrum that may include gross or microscopic hematuria,
proteinuria, and nephrotic syndrome. Renal dysfunction and
hypertension may also be present in many patients.
Etiopathogenesis of GN also varies, being idiopathic in a
large majority, while some may result from infections, such
as hepatitis or human immunodeficiency virus-1 [HIV-1], or
from known immune disorders, such as systemic lupus
erythematosus [SLE].
CLASSIFICATION
From a clinical perspective, GN can be classified as acute
or chronic (Table 1). A sub-group of patients with acute GN
designated as “rapidly progressive GN” [RPGN] have an
aggressive clinical presentation, progressive decline of renal
function occurring over days to weeks, and presence of
crescents around the glomerular tufts in renal biopsy.
Chronic GN, on the other hand, has an indolent clinical
course, usually presenting with proteinuria, nephrotic
syndrome, hypertension and variable degree of renal
dysfunction. Renal pathology in chronic GN is variable. Of
course, some disorders overlap in classification, since they
can cause both acute and chronic GN. This review will
discuss common forms of acute GN seen in children.
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ACUTE POST-STREPTOCOCCAL GLOMERULONEPHRITIS
Acute post-streptococcal GN [APSGN] is the most
common form of GN encountered in children. WHO
estimates that 472,000 patients are affected globally with
APSGN each year, and results in 5,000 deaths annually [2].
Most of the mortality is related to complications in the acute
phase of the disease.
Epidemiology
Although APSGN may occur at any age, it is more
commonly encountered between the age of 2 and 15 years
[3-5]. Occurrence of APSGN below the age of 2 years is rare
[6]. A declining trend in APSGN has been well documented
in the United States from early1960s, especially in the
impetigo associated disease [7]. In a recent analysis of
APSGN, Ilyas noted that the prevalence of the disease had
decreased from 2.18/100,000 population in the 1959-1973
cohort, to 0.64/100,000 in the 1999-2006 cohort [8].
ASPGN, however, remains a public health concern in
developing countries, especially in the tropical regions [9].
APSGN follows upper respiratory or skin infection with
group A β-hemolytic Streptococcus. Pharyngotonsillitis is a
more common antecedent to APSGN in temperate climates
and occurs during winter and spring months. Impetigoassociated APSGN, on the other hand, is more common
during summer and autumn months and occurs more
frequently in the tropical regions [7-9].
Clinical Manifestations
The onset of APSGN usually occurs 7-14 days after
pharyngotonsillitis, but can be longer in the impetigoassociated disease [10]. Typical clinical features of APSGN
consists of a combination of gross hematuria, oliguria,
hypertension, mild lower extremity or periorbital edema, and
a modest impairment in renal function (Fig. 1). Dull
2015 Bentham Open
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Classification of glomerulonephritis in children.

Classification of Glomerulonephritis in Children
1.

Acute glomerulonephritis
•
Acute post-infectious glomerulonephritis
Post-streptococcal GN
GN of infective endocarditis
Shunt nephritis
•

Acute glomerulonephritis associated with systemic disorders
Systemic lupus erythematosus
Henoch-Schonlein purpura
Microscopic polyangitis and other vasculitic disorders
Wegener's granulomatosis
Antiglomerular basement membrane [AntiGBM] antibody mediated glomerulonephritis [ Goodpasture
syndrome]

2.

Chronic glomerulonephritis
•
Focal segmental glomerulosclerosis [FSGS]
•
Membranoproliferative glomerulonephritis [MPGN]
•
Membranous glomerulonephritis
•
Immunoglobulin A [IgA] glomerulonephritis or nephropathy

3.

Rapidly progressive glomerulonephritis
•
Anti-neutrophil cytoplasmic autoantibody [ANCA] associated crescentic glomerulonephritis
•
Immune complex mediated crescentic glomerulonephritis
•
Membranoproliferative glomerulonephritis [MPGN]
•
Post-sterptococcal glomerulonephritis
•
Immunoglobulin A [IgA] glomerulonephritis or nephropathy
•
Antiglomerular basement membrane [AntiGBM] antibody mediated glomerulonephritis [ Goodpasture syndrome]

abdominal pain or flank pain and malaise may be present [3,
4, 10]. Mild fever can be seen in about half of the patients,
often attributed to an underlying tonsillopharyngitis. Gross
hematuria may last for a few weeks, but microscopic
hematuria may persist for several months.
Hypertension is a common finding in patients with
APSGN, occurring in over 80% of cases [4-6, 11]. Severe
hypertension,
hypertensive
encephalopathy
and
radiographically defined posterior reversible encephalopathy
syndrome [PRES] have also been reported [12]. Mild

pretibial and periorbital edema, caused by fluid retention and
oliguria are noted in most patients. Severe fluid overload and
pulmonary edema may be seen in some (Fig. 2).
Asymptomatic APSGN may occur in contacts or family
members of index cases [13].
Pathogenesis
In the past, Streptococcal M antigen has been considered
as the primary nephritogenic antigen involved in the

Fig. (1). Time course of clinical and laboratory manifestations of post-streptococcal glomerulonephritis. Reproduced with permission from:
Clinical Pediatric Nephrology, 3rd edition. Kher K, Schnaper HW, Greenbaum LW [Editors]. Taylor and Francis, Oxford, UK.
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glomerular inflammatory response in APSGN [14].
Available evidence, however, does not support the relevance
of M antigen as a nephritogenic antigen [15]. Studies done in
the last two decades have focused on two separate antigens,
and possibly others which may be involved in the
pathogenesis of APSGN. These antigens are: 1] nephritisassociated plasmin receptor [NAPlr], and 2] streptococcal
pyrogenic exotoxin B [SPeB]. Once deposited in the
glomerulus, both of these antigens induce complement
activation, and promote glomerular tissue injury, induce
chemoattractants and inflammatory response in the
mesangial and endocapillary sites [16-18].
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antibody. ASO titer may not be significantly elevated in
some patients early in the course of the disease and should be
repeated to demonstrate a rising titer. ASO titers may remain
low in patients with impetigo-associated APSGN. A
decrease in serum complement C3 resulting from its
consumption in APSGN is seen in the majority of patients
early in the disease, and the decrease is profound in some
patients. Complement C4 is usually normal but low levels
have been noted in a minority of patients [19].
Renal dysfunction, characterized by elevated blood urea
nitrogen [ BUN], and serum creatinine are seen transiently.
Hyperkalemia is common in most patients and can be severe
in some. A rising serum creatinine level and worsening of
oliguria may be indicators of RPGN. These patients warrant
a diagnostic renal biopsy.
Renal Biopsy

Fig. (2). Chest X-ray of a patient with post-streptococcal
glomerulonephritis showing pulmonary edema. He presented with
difficulty in breathing, oliguria and “brownish urine”.

Diagnosis
Apart from clinical features, the diagnosis of APSGN is
established by : 1] demonstration of a rise of antibodies
against streptococcal antigens, and 2] documenting a
decrease in the serum complement C3. Two streptococcal
antibodies that are commonly employed in the diagnosis are:
a] anti-streptolysin O [ASO] titer, and b] anti-DNAse B

Renal biopsy is not necessary in most patients with
APSGN. In patients with RPGN, the presence of significant
proteinuria or non-resolving renal disease, a renal biopsy is
an important diagnostic tool. The characteristic findings of
APSGN on renal biopsy consist of cellular proliferation
within the glomeruli, chiefly affecting the endothelial cells
and mesangium. Polymorphonuclear infiltration within the
inflamed glomeruli is also usually present. In cases with
RPGN, extraglomerular proliferation and crescent formation
are usually present. Immunofluorescence microscopy shows
immune deposits consisting of immunoglobulin G [IgG],
along with complement C3. Electron-microscopy
demonstrates presence of large sub-epithelial electron dense
deposits or humps (Fig. 3).
Treatment
Most patients with APSGN respond well to conservative
therapy consisting of: 1] fluid restriction, 2] sodium and
potassium restriction, 3] treatment of fluid overload with
diuretics, and 4] treatment of hypertension. Loop diuretics
[furosemide] may also be helpful in decreasing serum
potassium level in patients with mild hyperkalemia.
Hyperkalemia may require treatment with potassium
exchange
resins
[sodium
polystyrene
sulfonate,
Kayexalate®]. Dialysis therapy may become necessary in

Fig. (3). Electron microscopy of renal biopsy in a patient with post-sterptococcal glomerulonephritis. A characteristic large subepithelial
electron dense deposit, or “hump” is seen [arrow].
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patients with severe renal dysfunction, hyperkalemia or fluid
overload, especially those with RPGN.
If group A beta hemolytic streptococci [GABS] are
documented in the throat culture, or from skin lesions, the
patient should be treated with appropriate antibiotic therapy.
Although antibiotic therapy does not alter the clinical course
of APSGN, elimination of nephritogenic group A beta
streptococci as a reservoir of infection is important from an
epidemiological perspective and preventing spread of the
infection in the community. Antibiotic therapy has been
found to be particularly helpful in curtailing the spread of
GABS in epidemics.
Prognosis
Mortality of APSGN during the acute phase of the
disease is well known and ~5000 deaths occur annually
around the globe according to WHO estimates [2]. The
mortality rate in developed countries has declined
dramatically. Hadiwijaya et al. reported a mortality rate of
5.2% in Indonesia, while none of the 220 patients reported in
a recent Japanese study died [20, 21]. Mortality during the
acute phase of the illness is usually due to complications,
such as hyperkalemia, fluid overload, hypertensive
emergencies and uremia.
Long-term prognosis of APSGN in children is excellent.
Microscopic hematuria usually resolves in 3-6 months but
may persist in a rare patient for as long as 4 years [21].
Proteinuria is usually transient in uncomplicated APSGN,
and resolves in a 2-12 weeks in over 80% cases, and in 98%
by the end of the first year [21]. Hypertension resolves in
most patients within the first two weeks, and renal function
normalizes around the same time.
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abnormalities in circulating serum IgA in both of these
disorders. Pathogenesis of the HSP is discussed below in
conjunction with IgA nephropathy.
Clinical Manifestations
Patients with HSP often present with history of a
prodrome, usually an upper respiratory infection, followed
by onset of abdominal pain, joint pain and swelling. Ankles
and knees are commonly affected, but other large joints may
also be affected. The child’s primary complaint may be
difficulty in walking. A typical rash consisting of palpable
purpuric lesions, usually begins around the medial malleolus
and spread towards buttocks (Fig. 4) [23]. Extensor surfaces
of the arms, particularly around elbows as well as the trunk
are also affected, but the face is usually spared. In a rare
patient, the onset of rash may be delayed by several weeks or
months in relation to gross hematuria or proteinuria. Scrotal
edema may be severe and may mimic testicular torsion [30].
Resolution of clinical symptoms usually occurs within two
weeks, and is often complete by 4 weeks. Recurrence of rash
is common and has been noted in 40-50% of cases,
especially with renal involvement. Recurrences commonly
occur in the first six months after the initial onset of the
disease [23, 31]. Less common manifestation include
cerebritis, pancreatitis, and pulmonary hemorrhage [32-34].

HENOCH-SCHÖNLEIN PURPURA NEPHRITIS
Henoch-Schönlein purpura [HSP] is a leukocytoclastic
vasculitis characterized by rash, systemic manifestations and
development of GN in some children. Most patients with GN
present as an acute clinical disorder, although an occasional
patient may develop chronic GN and nephrotic syndrome,
with progressive decline in renal function.
Epidemiology
The incidence of HSP has been estimated to be ~20.4 per
100,000 population per year [22]. HSP primarily affects
children younger than 10 years of age. Mean age at onset is
~6 years with slight male preponderance, but the disease has
been reported in children as young as 6 months of age [23,
24]. The disease is more common in the fall and spring [2327]. Geographic clustering, or micro-epidemics have also
been reported occasionally [28].
Pathogenesis
HSP and IgA nephropathy are now considered to be the
two ends of the spectrum of the same disease. Some have
gone so far as to characterize IgA nephropathy as HSP
without rash [29]. This is based on the observation of similar
renal pathology and immunofluorescence findings, as well as

Fig. (4). Characteristic rash in the lower extremities in a patient
with Henoch-Schönlein purpura. Patient had mild nephritis,
characterized by microscopic hematuria.
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Renal disease in HSP characterized by microscopic or
gross hematuria, proteinuria and nephrotic syndrome, occurs
in 30-40% cases [23, 33]. Of these, hematuria is the most
common feature. Mild proteinuria occurs in about 25% of
unselected cases [23]. Severe proteinuria, nephrotic
syndrome or nephritic-nephrotic manifestations [hematuria,
proteinuria, renal dysfunction] occur in 5-10% of patients,
and indicates severe renal disease [23, 35]. These patients
require close follow up and monitoring.

Numerous studies have documented an adverse outcome
of severe renal disease in HSP. Those with nephriticnephrotic clinical features, nephrotic syndrome, renal
dysfunction, and hypertension at presentation are at an
increased risk to develop chronic kidney disease [CKD ] and
ESRD later on [43-48]. Treatment of this subset of children
remains controversial. Data on the use and effectiveness of
corticosteroids in these patients is unclear, since these have
often
been
used
in
conjunction
with
other
immunosuppressive agents [49].

Diagnosis

Addition of cyclophosphamide to corticosteroids has
been reported to be beneficial in patients with severe HSP
nephritis [50]. In contrast, Tarshih et al. conducted a
randomized controlled trial of 28 patients with histologically
severe HSP nephritis who were treated with
cyclophosphamide orally at a dose of 90mg/m2/day for 42
days [51]. Another 28 patients in the control group received
only supportive care. Cyclophosphamide treatment did not
improve the renal outcome of patients, as judged by
incidence of CKD or ESRD.

European League Against Rheumatism/ Paediatric
Rheumatology International Trials Organisation/ Paediatric
Rheumatology European Society has proposed the following
criteria for diagnosis of HSP with the mandatory presence of
purpura or petechiae with lower limb predominance, plus
one of four criteria: [1] abdominal pain; [2] skin biopsy
demonstrating IgA; [3] arthritis or arthralgia; and [4] renal
involvement manifesting as microscopic or gross hematuria
and proteinuria [36]. BUN and serum creatinine elevation
may be seen in those with significant nephritis. Patients with
severe HSP nephritis may present with the nephrotic
syndrome. Serum complement C3 is usually normal, but may
be decreased in some patients [23, 37]. Evidence of recent
streptococcal infection may be seen in up to 20-30% cases
[23].
The presence of IgA in the skin biopsy of patients with
HSP is well known, and has been recognized as a diagnostic
criterion of vasculitis in this disorder [36, 38]. Indeed, a skin
biopsy rather than a renal biopsy has been considered as an
adequate diagnostic test in patients with HSP nephritis [39].
In most cases of HSP nephritis, however, a renal biopsy is
not necessary. Patients with progressive proteinuria or
progressive decrease in renal function should be referred to a
pediatric nephrologist, and a renal biopsy should be
considered. A rapidly increasing serum creatinine in these
patients may be indicative of crescentic or RPGN. An early
renal biopsy and institution of therapy is an important key to
renal outcome in such patients.
Treatment
Treatment of most patients with HSP is largely
symptomatic
and
supportive.
Non-steroidal
antiinflammatory drugs [NSAID] may be used for relief of joint
pain. Use of oral corticosteroids has been shown to be
effective in ameliorating the symptoms of abdominal pain in
HSP [40]. The prednisone dose is usually 1-2 mg/kg /day for
1-2 weeks, and then tapered.
Evidence based data on management of HSP nephritis is
scant. Corticosteroids have not been shown to be effective in
preventing nephritis in double blind controlled trials [40].
However, in a meta-analysis of published literature [1956 to
January 2007] corticosteroids were noted to reduce the odds
of developing persistent renal disease [41]. Mild nephritis,
characterized by hematuria and sub nephrotic proteinuria
usually resolves on its own and does not require intense
corticosteroid treatment or immunotherapy [42]. Urinary
findings usually abate in 4-6 weeks in these patients.

Other immunosuppressive agents that have been used in
the treatment of severe HSP nephritis include azathioprine
and mycophenolate mofetil [MMF] [52-54]. The role of
MMF in the treatment of HSP nephritis was encouraging in
early studies [53, 54]. Du et al. used MMF in a dose of 20 to
25 mg/kg per day in 12 children with severe HSP nephritis
and nephrotic range proteinuria [ mean 5.6 grams per day]
for 10-15 months [53]. After a mean follow up of 3.9 years,
all patients were free of proteinuria and all had normal renal
function. Similarly, cyclosporine has also been useful in
inducing remission of proteinuria in HSP nephritis and
severe proteinuria [55]. Although effective, cyclosporine A
dependence has been noted in some of these patients.
Rituximab has been shown to be effective in inducing
remission of patients with severe HSP nephritis who were
refractory to other therapies [56]. Role of plasmapheresis in
HSP nephritis is unclear. Some small studies have shown an
improvement in patients with HSP and cerebritis, but others
have no clear benefit in HSP associated RPGN [57, 58].
Prognosis
The overall mortality of HSP nephritis is less than 1%,
with most deaths occurring due to complications, such as
hypertensive encephalopathy and systemic disease [35].
Although remission is common in many patients with HSP
nephritis, residual renal disease can occur in a high
proportion of children affected by this disease [35, 45]. In 64
children with biopsy proven HSP nephritis, Schärer et al.
demonstrated renal survival in 79%, but CKD, ESRD or
death occurred in 21% of cases [35]. Of those with renal
survival, 37% eventually had complete clinical remission,
30% had minor urinary abnormalities [sub-nephrotic range
proteinuria, no hypertension, normal renal function], and
12% had active renal disease [high grade proteinuria,
with/without hypertension]. Hematuria alone, without
associated proteinuria has been noted to have excellent long
term outcome [39]. In a review of 1133 children with HSP,
Narchi [48] noted that CKD never developed in patients with
normal urinalysis but was seen in 1.6% of those with isolated
urinary abnormalities, and in 19.5% of those who developed
nephritic or nephrotic syndrome. The authors recommended
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follow up for 6 weeks after disease onset, since proteinuria
can develop subsequent to the initial presentation.
Factors associated with poor renal outcome include: 1]
high grade or nephrotic range proteinuria, 2] nephriticnephrotic presentation [proteinuria, hematuria, hypertension
and renal dysfunction], 3] renal failure at initial presentation,
and 4] severe renal biopsy changes, such as presence of
crescents [35, 44-46, 59, 60]. Interestingly, in a large Turkish
study of 179 children who underwent renal biopsy for HSP
nephritis, no correlation was found between presence of
crescents in the renal biopsy and long term outcome [61].
Renal outcome of HSP nephritis in adults, especially in
females, has been noted to be worse than in children and
males [47]. Recurrence of HSP nephritis in renal transplants
has been reported, sometimes leading to graft loss [62].
IGA NEPHROPATHY
IgA nephropathy [IgAN], also known as Berger’s
disease, was described as a distinct entity by Berger and
Hinglais in 1968 in patients who had evidence of
microscopic or gross hematuria as the dominant clinical
manifestation [63]. IgAN now constitutes the commonest
form of chronic GN in adults and accounts for about 50% of
adults with CKD and ESRD world-wide [64, 65].
Epidemiology
The true incidence of IgAN is unclear. In the United
States, IgAN accounts for ~10%, of all renal biopises [66]. In
contrast, 20-35% of native kidney biopsies performed in
Korea and Japan are diagnosed to have IgAN [67, 68]. South
West Pediatric Nephrology group reported that 52% of
children biopsied for gross hematuria carried the diagnosis of
IgAN [69]. IgAN has been reported across all racial groups.
One single center study reported that the incidence of IgAN
may actually be higher among African American children in
the United States [70]. Although not a familial disorder,
large kindred of IgAN patients have been described in the
United States and Italy [71, 72].
Clinical Manifestations
Patients with IgAN may present with dramatic symptoms
of gross hematuria that follows an upper respiratory tract
infection in the preceding 12-72 hours. This has often been
labeled as “synpharyngetic hematuria” [73, 74]. Gross
hematuria in APSGN, in contrast, occurs 10-14 days
following a streptococcal URI. Gross hematuria usually lasts
a few days, followed by microhematuria that can also vary in
duration from few days to several weeks. Normal urinalysis
may be seen in many patients with IgAGN. Proteinuria is
usually seen early in the course of the disease. Nephrotic
range proteinuria and nephrotic syndrome may be seen in
patients with morphologically severe disease. Recurrent
bouts of gross hematuria following URI are common in
patients with IgAN, while persistent microhematuria may be
a manifestation in about 50% of affected children. Clinical
manifestations of IgAN in African American population
conform to those seen in the Caucasian race [75].
A secondary form of IgAN has been described in patients
with liver disease, such as cirrhosis [76]. Gastrointestinal
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disorders, such as celiac disease and dermatitis herpetiformis
are also known to be associated with IgAN [77, 78]. IgAN
has also been reported in association with viral infections,
such as HIV, and hepatitis A, B and C infections [79-82].
Pathogenesis
The pathogenesis of IgAN and HSP is not entirely clear.
A ‘four hit” model for pathogenesis of IgAN has been
proposed [83-85]. The first hit is a genetic predisposition to
produce an abnormal IgA1 molecule in both of these
disorders. Circulating IgA1produced by B cells in response
to respiratory infection in patients with IgAN and HSP is
deficient in galactose in the hinge region of the heavy chains.
The second hit consists of developing autoantibodies against
the abnormal galactose deficient-IgA1. These antibodies can
be either IgG or IgA. The third hit consists of deposition of
IgA1-antibody complexes in the glomerular mesangium, a
process that is less well defined. The mesangial immune
complexes may be developed in-situ or result from
deposition of circulating immune complexes. The fourth hit
is the initiation of inflammatory pathways and local
activation of complement within the glomeruli, and release
of cytokines in the glomerular tissues. It is this final pathway
that leads to glomerular injury and inflammation [83-86].
The pathogenesis of IgAN and HSP is believed to be
similar, and the two disorders are believed to be the spectral
ends of the same disorder. Some even go so far as to
designate IgAN as “HSP without rash” [87, 88].
DIAGNOSIS
The diagnosis of IgAN requires a renal biopsy. However,
during an initial discovery of microscopic hematuria, or first
episode of gross hematuria, the diagnosis of APSGN needs
to be ruled out (Table 2) by serum complement C3 level
determination and evidence for GABS [ASO titer, antiDNAse B, throat culture]. Renal function tests,
quantification of proteinuria by a 24- hour urine collection or
first morning urine protein/creatinine ratio should also be
assessed. Elevated levels of abnormal galactose-deficient
IgA1 levels are noted in 70-80% of patients with IgAN [89].
However, this test may not be available commercially in
most clinical laboratories.
Other conditions that present with gross hematuria, and
need to be considered in the differential diagnosis include
Alport syndrome, thin-basement membrane nephropathy
[TBMN] and membranoproliferative GN [MPGN]. Systemic
lupus nephritis also presents with gross or microscopic
hematuria and proteinuria, and should be ruled out by
appropriate laboratory evaluation. All of the above
mentioned clinical conditions also need a renal biopsy for
confirmation of the clinical diagnosis.
Renal Biopsy
Renal biopsy findings in IgAN and HSP are similar; both
disorders showing a variably increased mesangial matrix and
cellularity on light microscopy. Immunofluorescence
microscopy (Fig. 5) demonstrates a dominant presence of
immunoglobulin A [IgA], along with complement C3 and
IgG [74, 90].
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Clinical features of acute glomerulonephritis associated with post-streptococcal disease, IgA nephropathy and HenochSchonlein pupura.

Clinical Parameters

Preceding URI

Acute Post-Streptococcal GN
Streptoccocal infection 10-14 days
before onset of gross hematuria.
Pyoderma associated APSGN:
latent period may be up to 6 weeks

IgA GN
24-72 hours before onset of
hematuria [synpharyngetic]. URI is
often viral in nature.

HSP Nephritis
May have preceding streptococcal
infection.
Streptococcal antibodies positive in
25-30%

Duration of hematuria

7-14 days

2-14 days. Recurrent gross
hematuria with URI.

Gross hematuria occurs in minority
of patients. Microhematuria is more
common

Microhematuria

Can persist up to 1 year

Can persist, but may disappear in
between gross hematuria.

Microhematuria is common, usually
resolves in few weeks.

Serum complement C3

Low

Normal

Normal

Hypertension
Other Clinical associations

Typical rash

Hyperkalemia

Acute kidney injury

Joint pains

Oliguria

Nephrotic syndrome

Abdominal pain

Mild azotemia

Renal Biopsy finding

Sub-epithelial “humps” - electron
dense deposits

Prognosis

Excellent

Risk for intessusception
Mesangial cell and matrix
proliferation

Mesangial cell and matrix
proliferation

Mesangial IgA, IgG and C3
complement deposits

Mesangial IgA, IgG and C3
complement deposits

Long-term risk of CKD and
hypertension.

Risk of CKD in only those with
severe renal pathology. Most
patients recover

Abbreviations: CKD=chronic kidney disease; HSP=Henoch-Schonlein purpura; IgA= immunoglobulin A; IgG= immunoglobulin G.

The International IgA Nephropathy Network and the
Renal Pathology Society has proposed Oxford classification
of IgAN or Oxford -MEST classification [91, 92]. This renal
biopsy classification utilizes the degree of mesangial
cellularity, segmental glomerulosclerosis, endocapillary
hypercellularity and tubulointerstitial fibrosis as the
parameters of scoring (Table 3). The severity of renal biopsy
is scored on a progressive scale of changes in each category,
and the final score is indicated by a composite of each aspect
of evaluation parameter. Although extraglomerular
proliferation [crescent formation] is generally regarded as an

indicator of poorer outcome in patients with GN, the Oxford
classification of IgAN did not consider it to be an important
variable in their study. In general, more severe morphologic
disease correlates with a worse long-term outcome.
Treatment
There is no clear consensus about treatment of IgAN.
Since proteinuria is considered a marker of progression of
renal disease in a variety of disorders, including IgAN,
treatment with angiotensin converting enzyme inhibitors

Fig. (5). Renal biopsy findings in patients with Henoch Schölnlein purpura nephritis and IgA nephropathy. (A) Light microscopy showing
moderate mesangial cell and matrix increase. Glomerular capillary loops are otherwise open. There is no evidence of extraglomerular
crescents in this case. (B). Immunofluorescence staining with IgA antibody, showing IgA immune deposits in the mesangial region.
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[ACEI] should be considered in IgAN patients with
significant or advancing proteinuria. Both ACEI and
angiotensin receptor blockers [ARB] have been found to be
useful in ameliorating proteinuria in children with IgAN [93,
94].
Table 3.

Oxford classification of renal biopsy scores in IgA
nephropathy. Based on and modified from :Working
Group of the International IgA Nephropathy
Network and the Renal Pathology SocietyThe
Oxford classification of IgA nephropathy: rationale,
clinicopathological correlations, and classification.
Kidney Int. 2009; 76: 534-45.

Morphologic Findings

Definition

Score

< 50% mesangial tufts with ≥ 3 cells

M0

> 50% mesangial tufts with ≥ 3 cells

M1

Absent

S0

Present

S1

Endocapillary hypercellularity [E] Absent

E0

Present

E1

Tubulointerstitial atrophy/

0-25% cortical area

T0

Fibrosis [T]

26-50% cortical area

T1

>50% cortical

T2

Mesangial cellularity [M]

Segmental sclerosis [S]

Corticosteroids alone may help patients with moderately
severe disease. However, randomized controlled trials using
corticosteroids alone in IgAN are limited. The South West
Pediatric Nephrology group studied the effects of daily
corticosteroid followed by alternate day therapy for a total of
2 years in children and young adults with IgAN. This study
did not demonstrate any superiority of treatment with
corticosteroids over placebo in preventing decline of GFR
[95]. A recent meta-analysis of published studies of IgA in
adults and children demonstrated that corticosteroid use in
IgAN was associated with a lower risk of renal disease and
proteinuria in the follow up periods [96]. Further subgroup
analysis of the data demonstrated that long term, low dose
use of steroids did not reduce the risk of renal disease. On
the other hand, high dose oral or intravenous costicosteroids
used for a short time was helpful in reducing the long-term
risk of renal disease in this analysis.
The role of MMF in the treatment of IgAN is unclear.
Several studies have demonstrated failure of a clear benefit
of MMF in the treatment of IgAN of varying severities [97,
98]. Transient and partial remission of proteinuria has,
however, been noted by some [98]. A metanalysis of MMF
used in IgA nephropathy also did not demonstrate any
benefit in the treatment of proteinuria or protecting decline in
renal function [99]. In children with IgAN resistant to steroid
therapy, combining corticosteroid treatment with MMF has
been noted to be beneficial in inducing remission of
proteinuria in 63% patients [100].
Omega3 fatty supplements [fish oil] had been thought to
be of benefit in ameliorating proteinuria in patients with
IgAN [95]. The anti-proteinuric effect of omega-3 fatty acid
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therapy may be dose dependent [101]. A meta analysis of
published data also suggested that despite ameliorating
proteinuria, omega-3 fatty acids did not demonstrate any
benefit in preventing a decline in renal function [102].
Combining corticosteroids with other immunosupressives, such as cyclophosphamide or azathioprine, alone or
with warfarin and dipyridamole has been attempted
[quadruple therapy]. In one such randomized controlled trial,
azathioprine showed improvement in renal survival [103].
Because of the high risk for CKD in patients with severe
renal pathology in patients with IgAN, most clinicians tend
to use a combination of intravenous corticosteroids, and
immunosupressives [azathioprine, MMF, cyclosporine].
Prognosis
IgAN has a better outcome in children than in adults.
Japanese experience with IgAN suggests that spontaneous
remission of hematuria is possible in ~50% of children with
the disease [104, 105]. Time to remission of hematuria and
proteinuria can be several years [5-6 years], and recurrence
of symptoms after prolonged remissions is well known
[105]. Persistent microscopic hematuria or recurrent gross
hematuria occurs in 35% cases and widely spaced or isolated
episodes of hematuria are present in 10-15% cases [73-75].
Frequency of gross hematuria or degree of microscopic
hematuria do not predict long term prognosis [106]. On the
other hand, the presence of proteinuria and its severity are
well known to predict renal outcome in IgAN [107, 108].
Evolution of ESRD, often as adults, is seen in ~20-25%
pediatric IgAN cases [73-75, 104, 109]. Finnish data
suggests that ESRD occur in 11% cases, while 39% were
being treated for hypertension and proteinuria after a mean
follow up of 18.7 years [range: 8.5-29.8 years] [109].
Available data in adults also suggests that renal outcome is
worse in those with the nephrotic syndrome [110]. The
severity of histological changes on renal biopsy at onset,
especially using the Oxford classification has also been
shown to be predictive of outcome [111, 112].
LUPUS NEPHRITIS
Systemic lupus erythematosus [SLE] is an autoimmune
disorder that is associated with GN and has a high potential
for CKD and ESRD. The clinical manifestations of SLE as
well as lupus nephritis [LN] in children are highly variable
and can simulate both acute and chronic GN at its onset. LN
often needs to be considered in the differential diagnosis of
acute nephritic syndrome and nephritic-nephrotic clinical
presentation.
Epidemiology
LN can be either the presenting manifestation, or
becomes evident at initial discovery of the disease in 60-80%
of children [113-115]. In general, SLE as well as LN are
more common in females. The disease is reported to be more
prevalent in Asian and African American girls, as compared
to Caucasians [116]. American College of Rheumatology
[ACR] criteria for diagnosis of LN are: 1] persistent
proteinuria defined as 0.5 g per day in a 24 hour urine
collection or first morning spot urine protein/creatinine ratio
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of 0.5] nephritic urine sediment consisting of red blood cells
[RBCs], granular, tubular, or mixed casts. 3] Serologic
diagnostic criteria of SLE, and 4] suggestive renal biopsy,
when available [117]. Presence of renal failure is not
included as a diagnostic criterion of LN in the current ACR
definition.
Pathogenesis
SLE is characterized by a disordered immune system,
wherein auto-antibodies are produced against numerous
“self” antigens, such as native DNA, cytoplasmic proteins
and nuclear proteins. The auto-antibodies, in turn, form
circulating and in-situ immune complexes that result in
inflammatory response in the affected tissues and organs.
Within the kidney, immune complex deposition, and
subsequent inflammatory response can affect the glomeruli,
tubulointerstitial space, as well as the vascular structures.
Variable involvement of these tissue compartments by the
inflammatory response and damage is common in patients
with LN.
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nephrotic clinical features, with edema, hematuria, acute
renal injury and hypertension are also commonly
encountered. Patients with class V [Membranous variant]
form of LN have heavy proteinuria and nephrotic syndrome
as a dominant clinical finding. On the other hand, class III
[diffuse proliferative] may have a nephritic-nephrotic
presentation with hematuria-proteinuria, hypertension and
elevated serum creatinine level. In an Italian registry of SLE
nephritis, nephrotic syndrome, hypertension, and renal
failure were present at onset in 40%, 28%, and 32%,
respectively [119].
Diagnosis
Apart from studies to establish the diagnosis of SLE by
various antibody titers and inflammatory markers, renal
biopsy is essential in establishing the diagnosis of LN.
Clinical features, urinary protein extcetion and urinary
sediment evaluation may not provide sufficient evidence to
diagnose LN in many patients, and “silent” LN has been well
documented [120].

Renal Pathology

Treatment

The type of morphologic lesions encountered in LN is
also diverse, ranging from almost normal glomeruli with
mild mesangial proliferation to severe and diffusely
proliferative GN. World Health Organization [WHO]
provided a clinically relevant classification system for LN
(Table 4) that has now been modified and enhanced by the
International Society of Nephrology and the Renal Pathology
Society [118].

Treatment of LN is largely dictated by the type of
pathology seen on renal biopsy and the severity of the
disease. Class I and II LN, which represent mild form of
nephritis, is usually treated with corticosteroids to control of
systemic disease. On the other hand, class III [focal
proliferative LN] and class IV [diffuse proliferative LN] can
be quite aggressive in their clinical course and carry a
potential of adverse long term renal outcome, such as CKD
and ESRD. For this reason, children affected by these classes
of renal pathology need aggressive immunosuppression.
Although numerous immunosuppressive options are now
available for treatment of class III and IV LN, inravenous
cyclophosphamide and MMF have emerged as the two
primary induction therapies in children in a recent consensus
statement [121].

Immunofluorescence microscopy in LN usually
demonstrates presence of immunoglobulins IgG, IgA and
IgM, along with complement components, often referred to
as “ full-house” immune deposition. Apart from the above
noted lesions, renal biopsy may also show tubulointerstitial
inflammation and fibrosis, presence of variable degrees of
extra-glomerular cellular crescents and reticular structures
Clinical Manifestations
Manifestations of LN are varied, and can be microscopic
or gross hematuria, along with proteinuria. NephriticTable 4.

Intravenous cyclophosphamide induction consists of
administering a total of six monthly doses, initiated at 500
mg/m2 body surface area. Subsequent doses can be increased
but not to exceed a maximum monthly dose of 1,500 mg
[121]. MMF induction is dosed at 600 mg/m2/dose twice

Original World Health Organization [WHO] classification of lupus nephritis. Modified from: Churg J, Sobin LH: Renal
Disease: Classification and Atlas of Glomerular Disease, Tokyo, Igaku-Shoin, 1982.

Pathologic Class

Renal Morphology

Class I

Normal glomeruli: but immune deposits are noted by immunofluorescence and electron microscopy

Class II

Mesangial alterations only
a) No mesangial hypercellularity, but mesangial immune deposits are seen
b) Mesangial matrix and cellular hypertrophy with immune deposits

Class III

Focal, proliferative glomerulonephritis: <50% glomeruli affected.

Class IV

Diffuse glomerulonephritis: >50% glomeruli affected. Severe mesangial, endocapillary, or mesangio-capillary proliferation and/or
extensive subendothelial deposits]

Class V

Membranous glomerulonephritis

Class VI

Advanced glomerulosclerisis
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daily, with a maximum dose of 1,500 mg taken two times per
day. Mycophenolate sodium [MPA; Myfortic®] may be used
as an alternative to MMF at a dose of 400 mg/m2/dose twice
daily and maximum dose of 1,080 mg twice daily. It is
important to monitor and prevent side effects, especially
bone marrow suppression and infection risks associated with
the immunosuppressive therapies [121, 122].

ESRD

= End stage renal disease

GN

= Glomerulonephritis

HSP

= Henoch-Schönlein purpura

IgAN

= IgA nephropathy

LN

= Lupus nephritis

Immunosuppressive drug dose should be adjusted to the
nadir white blood cell count. Extra-renal manifestations and
the activity level of the disease should also be monitored
during induction therapy. Glucocorticosteroids are often
prescribed at modest doses during induction of LN. Total
duration of induction regimens lasts 6 months, after which
the patients are gradually returned to a maintenance schedule
of either corticosteroids alone, or in combination with MMF.

MMF

= Mycophenolate mofetil

RPGN

= Rapidly progressive glomerulonephritis

SLE

= Systemic lupus erythematosis

The treatment of choice for class V [membranous
nephritis] LN is with calcineurin inhibitor agents, such as
cyclosporine, since they respond less favorably to
corticosteroids and cyclophosphamide. Austin et al.
demonstrated that at 1 year, the cumulative probability of
remission was 27% with prednisone, 60% with intravenous
cyclophosphamide and 83% with cyclosporine [123]. Data
on the use of tacrolimus in LN is scant.
Prognosis
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